The global market for DNA Probes-based Diagnostics is projected to reach US$20.2 billion by 2022, driven by the growing use of DNA Probes in infectious disease testing, development of new methods for high-volume testing, launch of new equipment facilitating execution of tests in a rapid and simple manner, newer technologies and innovation that enhances test accuracy, speed, and reliability.
The global market for DNA probes-based diagnostics is expected to witness stable growth in the coming years, driven by factors such as rising awareness among consumers, aging population, rise in genetic disorders, technological developments as well as higher investments in pharmaceutical research. In addition to medical diagnostics, the DNA Probes-based technology is expected to grow considerably in other application areas, including surface chemistry, instrumentation development, data handling, molecular biology, biological sample preparation, microfabrication and molecular detection. In the [medical diagnostics] sector, DNA Probes-based diagnostics are used in identifying genetic predispositions, infectious diseases, molecular HLA typing, forensics, and cancer testing, among others.
Infectious disease testing is witnessing a growth spurt supported by the emergence of new infectious threats, such as new strains of HIV, H1N1, and multidrug-resistant tuberculosis etc. HPV diagnostic testing offers enormous growth opportunities as only a small share of women (aged over 30 years) are screened for HPV under the current standard of care involving pap smear and other DNA-based tests. However, as the technology climbs up the knowledge curve, falling costs are expected to make DNA based diagnostics affordable, more common and easy-to-use. Moreover, with newer MDx being developed along with rapid adoption of molecular biomarker assays, the market will continue to witness steady gains. Despite the opportunities for growth, the market is currently limited by high prices, technology loopholes/bottlenecks, and lack of standardization across test platforms.
Prenatal DNA testing is used to detect fetal chromosomal abnormalities, with same efficacy as invasive techniques such as CVS and amniocentesis, but without the risk of miscarriage. Therefore, it is being increasingly preferred to serve women with a high risk of carrying babies with chromosomal aneuploidies that may result in Down syndrome, among others. The tests are also covered by most U.S. health insurers. Nevertheless, DNA-based tests are still considered as screening tools. Positive test cases are recommended to be confirmed with conventional amniocentesis. However, invasive confirmatory tests can now only be restricted to only high-risk population
The U.S. and Europe constitute key markets worldwide with 80%-90% of tests being conducted in these regions. Emerging markets of Asia-Pacific and Latin America are forecast to spur future growth supported by government funding in medical research, introduction of advanced technologies, robust network of pharmaceutical and biotechnology industries. Asia-Pacific ranks as the fastest growing market, with a CAGR of 14.8% over the analysis period. Emerging Asian economies offer high potential given its large population base, rising healthcare burden, improving awareness, and access to medical products and services.
Major players in the market include Abbott Molecular, Affymetrix Inc., Beckman Coulter Inc., Becton, Dickinson and Company, bioMerieux, F. Hoffmann-La Roche Ltd., GE Healthcare Life Sciences, Luminex Corporation, QIAGEN N.V., Siemens Healthineers and Thermo Fisher Scientific Inc. among others.